AstraZeneca announced Tuesday morning that the company is investing $300 million in a state-of-the art facility in Rockville that will enable the company to launch its cell therapy platforms throughout the country.
These advances will be used in cancer trials and future commercial supply, according to an announcement from AstraZeneca, a science-led biopharmaceutical company.
About 150 skilled jobs will be created. Those employees are expected to focus on manufacturing T-cell therapies.
“AstraZeneca and the State of Maryland share a deep commitment to innovation. It makes us the perfect pairing for this next-generation cell therapy facility,” said Gov. Wes Moore. “This significant investment in our life sciences sector will help maintain Maryland’s leadership in the industry and sharpen our competitive edge.”
Pam Cheng, Executive Vice President of Global Operations & IT and Chief Sustainability Officer, AstraZeneca, announced, “We are incredibly excited that more than 150 new highly skilled jobs are being created to bring our scientific work and therapies to clinical trials which could transform the lives of patients around the world. ”
She added, “This new $300 million investment will accelerate our ambition to make next-generation cell therapy a reality, ensuring that we are ready to scale and meet the demands of patients.”
The new facility is located less than five miles from one of AstraZeneca’s five global research and development centers and is in Montgomery County’s life sciences corridor.
The global company’s portfolio involves allowing a person’s immune system’s T-cells to fight cancer.
